Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1–R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
Type:
Grant
Filed:
December 30, 2003
Date of Patent:
July 4, 2006
Assignee:
Pfizer, Inc.
Inventors:
Mark A Dombroski, Allen J. Duplantier, Chakrapani Subramanyam